ranixal 150 mg poretabletti
ratiopharm gmbh - ranitidini hydrochloridum - poretabletti - 150 mg - ranitidiini
magnesiamaito 82.5 mg/ml oraalisuspensio
orion corporation - magnesium hydroxide pasta - oraalisuspensio - 82.5 mg/ml - magnesiumhydroksidi
ranisan 150 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini
tagrisso
astrazeneca ab - osimertinib mesilate - karsinooma, ei-pienisoluinen keuhko - muut antineoplastiset aineet, proteiinikinaasin estäjät - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
marevan 3 mg tabletti
orion corporation - warfarin sodium - tabletti - 3 mg - varfariini
marevan forte 5 mg tabletti
orion corporation - warfarin sodium - tabletti - 5 mg - varfariini
novantrone 2 mg/ml infuusiokonsentraatti, liuosta varten
meda oy - mitoxantroni hydrochloridum - infuusiokonsentraatti, liuosta varten - 2 mg/ml - mitoksantroni
sporanox 100 mg kapseli, kova
janssen-cilag oy - itraconazole - kapseli, kova - 100 mg - itrakonatsoli
sporanox 10 mg/ml oraaliliuos
janssen-cilag oy - itraconazole - oraaliliuos - 10 mg/ml - itrakonatsoli
mitoxantron ebewe 2 mg/ml infuusiokonsentraatti, liuosta varten
ebewe pharma ges.m.b.h. nfg.kg - mitoxantrone hydrochloride - infuusiokonsentraatti, liuosta varten - 2 mg/ml - mitoksantroni